Altimmune(US:ALT) Prnewswireยท2025-10-01 12:13Core Viewpoint - A class action lawsuit has been filed against Altimmune Inc. by Berger Montague PC on behalf of investors who acquired Altimmune securities between August 10, 2023, and June 25, 2025, following disappointing trial results for its drug Pemvidutide [1][2][3]. Company Overview - Altimmune Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focusing on therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) [2]. Legal Action Details - The lawsuit is based on a press release issued by Altimmune on June 26, 2025, which announced that the IMPACT Phase 2b trial of Pemvidutide failed to achieve statistical significance in its primary endpoint related to fibrosis reduction, attributed to a higher-than-expected placebo response [3]. - Following the announcement, Altimmune's stock price plummeted by 53.2%, dropping from a close of $7.71 on June 25, 2025, to $3.61 on June 26, 2025 [4]. Investor Information - Investors who purchased Altimmune securities during the class period have until October 6, 2025, to seek appointment as lead plaintiff representatives [2].